Recent genetic advances in ADHD and diagnostic and therapeutic prospects

Ziarih Hawi, Aiveen Kirley, Naomi Lowe, Michael Fitzgerald, Michael Gill

Research output: Contribution to journalReview ArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine, serotonin and norepinephrine neurotransmitter systems in ADHD. Several investigations have pointed to the dopamine transporter, the dopamine receptors D4 and D5 and the serotonin transporter as genes of minor effect for ADHD. In addition, recent molecular analysis have also implicated synaptosomal-associated protein-25 and the serotonin receptor 5-Hydroxtryptamine 1B as potential susceptibility loci for ADHD. An understanding of the genetics of ADHD will further facilitate refinement and validation of the ADHD diagnosis, and the development of reliable disease markers in the prediction of disease risk. A knowledge of genes that determine treatment response has the potential to be of predictive value and may also assist in rationalizing drug treatment in the ADHD population. However, increased understanding of inheritance brings its own challenges in the interpretation of new knowledge and in its wise and ethical use, especially in relation to future screening of at-risk individuals. This article attempts to review recent genetic advances and their possible implications for improved diagnosis and treatment.

Original languageEnglish
Pages (from-to)453-464
Number of pages12
JournalExpert Review of Neurotherapeutics
Volume3
Issue number4
Publication statusPublished - Jul 2003
Externally publishedYes

Keywords

  • ADHD
  • Animal model
  • Diagnostic
  • Dopamine
  • Norepinephrine
  • Serotonin
  • Therapeutic implications

Cite this

Hawi, Z., Kirley, A., Lowe, N., Fitzgerald, M., & Gill, M. (2003). Recent genetic advances in ADHD and diagnostic and therapeutic prospects. Expert Review of Neurotherapeutics, 3(4), 453-464.
Hawi, Ziarih ; Kirley, Aiveen ; Lowe, Naomi ; Fitzgerald, Michael ; Gill, Michael. / Recent genetic advances in ADHD and diagnostic and therapeutic prospects. In: Expert Review of Neurotherapeutics. 2003 ; Vol. 3, No. 4. pp. 453-464.
@article{bf0b6f233fcf4d4fa9d86d2cf38f0165,
title = "Recent genetic advances in ADHD and diagnostic and therapeutic prospects",
abstract = "Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine, serotonin and norepinephrine neurotransmitter systems in ADHD. Several investigations have pointed to the dopamine transporter, the dopamine receptors D4 and D5 and the serotonin transporter as genes of minor effect for ADHD. In addition, recent molecular analysis have also implicated synaptosomal-associated protein-25 and the serotonin receptor 5-Hydroxtryptamine 1B as potential susceptibility loci for ADHD. An understanding of the genetics of ADHD will further facilitate refinement and validation of the ADHD diagnosis, and the development of reliable disease markers in the prediction of disease risk. A knowledge of genes that determine treatment response has the potential to be of predictive value and may also assist in rationalizing drug treatment in the ADHD population. However, increased understanding of inheritance brings its own challenges in the interpretation of new knowledge and in its wise and ethical use, especially in relation to future screening of at-risk individuals. This article attempts to review recent genetic advances and their possible implications for improved diagnosis and treatment.",
keywords = "ADHD, Animal model, Diagnostic, Dopamine, Norepinephrine, Serotonin, Therapeutic implications",
author = "Ziarih Hawi and Aiveen Kirley and Naomi Lowe and Michael Fitzgerald and Michael Gill",
year = "2003",
month = "7",
language = "English",
volume = "3",
pages = "453--464",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Taylor & Francis",
number = "4",

}

Hawi, Z, Kirley, A, Lowe, N, Fitzgerald, M & Gill, M 2003, 'Recent genetic advances in ADHD and diagnostic and therapeutic prospects', Expert Review of Neurotherapeutics, vol. 3, no. 4, pp. 453-464.

Recent genetic advances in ADHD and diagnostic and therapeutic prospects. / Hawi, Ziarih; Kirley, Aiveen; Lowe, Naomi; Fitzgerald, Michael; Gill, Michael.

In: Expert Review of Neurotherapeutics, Vol. 3, No. 4, 07.2003, p. 453-464.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Recent genetic advances in ADHD and diagnostic and therapeutic prospects

AU - Hawi, Ziarih

AU - Kirley, Aiveen

AU - Lowe, Naomi

AU - Fitzgerald, Michael

AU - Gill, Michael

PY - 2003/7

Y1 - 2003/7

N2 - Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine, serotonin and norepinephrine neurotransmitter systems in ADHD. Several investigations have pointed to the dopamine transporter, the dopamine receptors D4 and D5 and the serotonin transporter as genes of minor effect for ADHD. In addition, recent molecular analysis have also implicated synaptosomal-associated protein-25 and the serotonin receptor 5-Hydroxtryptamine 1B as potential susceptibility loci for ADHD. An understanding of the genetics of ADHD will further facilitate refinement and validation of the ADHD diagnosis, and the development of reliable disease markers in the prediction of disease risk. A knowledge of genes that determine treatment response has the potential to be of predictive value and may also assist in rationalizing drug treatment in the ADHD population. However, increased understanding of inheritance brings its own challenges in the interpretation of new knowledge and in its wise and ethical use, especially in relation to future screening of at-risk individuals. This article attempts to review recent genetic advances and their possible implications for improved diagnosis and treatment.

AB - Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine, serotonin and norepinephrine neurotransmitter systems in ADHD. Several investigations have pointed to the dopamine transporter, the dopamine receptors D4 and D5 and the serotonin transporter as genes of minor effect for ADHD. In addition, recent molecular analysis have also implicated synaptosomal-associated protein-25 and the serotonin receptor 5-Hydroxtryptamine 1B as potential susceptibility loci for ADHD. An understanding of the genetics of ADHD will further facilitate refinement and validation of the ADHD diagnosis, and the development of reliable disease markers in the prediction of disease risk. A knowledge of genes that determine treatment response has the potential to be of predictive value and may also assist in rationalizing drug treatment in the ADHD population. However, increased understanding of inheritance brings its own challenges in the interpretation of new knowledge and in its wise and ethical use, especially in relation to future screening of at-risk individuals. This article attempts to review recent genetic advances and their possible implications for improved diagnosis and treatment.

KW - ADHD

KW - Animal model

KW - Diagnostic

KW - Dopamine

KW - Norepinephrine

KW - Serotonin

KW - Therapeutic implications

UR - http://www.scopus.com/inward/record.url?scp=0041814509&partnerID=8YFLogxK

M3 - Review Article

VL - 3

SP - 453

EP - 464

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 4

ER -